Vertex Pharmaceuticals has invested £10.5 million in the British analytics company as the companies launch a multiyear R&D partnership seeking novel drug targets.
The grants are designed to help investigators working within groups pursue independent research and advance their careers in genomic science.
Researchers at the annual Association of Biomolecular Resource Facilities meeting said they are joining single-cell sequencing to other single-cell analyses.
The partners plan to share information about joint R&D activities and establish research facilities and laboratory infrastructure in Ethiopia.
The bill aims to reduce barriers to the use of genetic and genomic testing, including for children on Medicaid with a suspected genetic disease.
The institute expects to announce its strategic plan in October 2020 to commemorate the 30th anniversary of the launch of the Human Genome Project.
Areas of concern are the recruitment of talented scientists, as well as retaining access to EU funding, European research collaborations, and clinical trials.
The agency aims to fund projects examining the ethical, legal, and social implications of human genome research.
The partners will explore the possibility of building a sequencing hub at the university for conducting local population cohort studies and diagnostic testing.
The new fund aims to advance data-driven innovations by investing in academic research on and the commercialization of genomic and other technologies.
An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.
The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.
In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.
Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.